用于治疗新冠肺炎的巴尼韦单抗-A单克隆抗体紧急使用授权。 - Suppr

Suppr

超能文献

An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19.

出版信息

JAMA. 2021 Mar 2;325(9):880-881. doi: 10.1001/jama.2020.24415.

DOI:10.1001/jama.2020.24415

PMID:33306087

Abstract

摘要

相似文献

An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19.用于治疗新冠肺炎的巴尼韦单抗-A单克隆抗体紧急使用授权。

JAMA. 2021 Mar 2;325(9):880-881. doi: 10.1001/jama.2020.24415.

An EUA for bamlanivimab and etesevimab for COVID-19.巴瑞替尼和依替西单抗用于治疗新冠肺炎的紧急使用授权。

Med Lett Drugs Ther. 2021 Apr 5;63(1621):49-50.

An EUA for bamlanivimab - a monoclonal antibody for COVID-19.巴米雷单抗（一种用于治疗新冠肺炎的单克隆抗体）的紧急使用授权。

Med Lett Drugs Ther. 2020 Nov 30;62(1612):185-186.

An EUA for sotrovimab for treatment of COVID-19.索托维单抗用于治疗新冠肺炎的紧急使用授权。

Med Lett Drugs Ther. 2021 Jun 28;63(1627):97-xx98.

An EUA for casirivimab and imdevimab for COVID-19.用于治疗新冠肺炎的卡西瑞维单抗和伊德维单抗紧急使用授权。

Med Lett Drugs Ther. 2020 Dec 28;62(1614):201-202.

Emergency Use Authorization for Bamlanivimab in Mild to Moderate COVID-19: Implications for Clinical Nurse Specialist Practice.巴瑞替尼用于轻至中度新冠肺炎的紧急使用授权：对临床护理专家实践的影响

Clin Nurse Spec. 2021;35(3):112-115. doi: 10.1097/NUR.0000000000000591.

An EUA for tocilizumab (Actemra) for COVID-19.托珠单抗（Actemra）用于治疗新冠肺炎的紧急使用授权。

Med Lett Drugs Ther. 2021 Jul 26;63(1629):113-114.

Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents.儿童和青少年 2019 冠状病毒病治疗中使用单克隆抗体疗法的初步指导。

J Pediatric Infect Dis Soc. 2021 May 28;10(5):629-634. doi: 10.1093/jpids/piaa175.

Monoclonal Antibodies Receive EUA to Treat Mild to Moderate COVID-19.单克隆抗体获得 EUA 用于治疗 COVID-19 轻症至中症。

Am J Nurs. 2021 Feb 1;121(2):26. doi: 10.1097/01.NAJ.0000734112.15618.f4.

COVID-19 Updates: Monoclonal Antibodies for COVID-19.新冠疫情最新消息：用于治疗新冠的单克隆抗体

Med Lett Drugs Ther. 2022 Jan 24;64(1642):16.

引用本文的文献

Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA.新冠肺炎的单克隆抗体治疗是否会影响大样本可推广人群的短期和长期结局？美国的一项回顾性队列研究。

BMJ Open. 2023 Aug 8;13(8):e069247. doi: 10.1136/bmjopen-2022-069247.

Exploiting -Gene Bias for Rapid, High-Throughput Monoclonal Antibody Isolation from Horses.从马中快速、高通量分离单克隆抗体的利用 - 基因偏向性。

Viruses. 2022 Sep 30;14(10):2172. doi: 10.3390/v14102172.

The Treatment of COVID-19 With Monoclonal Antibody Therapy: Patient-Reported Outcomes.采用单克隆抗体疗法治疗新冠病毒病：患者报告的结果

Cureus. 2022 Sep 16;14(9):e29247. doi: 10.7759/cureus.29247. eCollection 2022 Sep.

Evidence Based Scarce Resource Allocation During the COVID-19 Pandemic: A Case Study of Bamlanivimab Administration in the Emergency Department.2019年冠状病毒病大流行期间基于证据的稀缺资源分配：急诊科巴瑞替尼给药案例研究

Hosp Pharm. 2022 Oct;57(5):639-645. doi: 10.1177/00185787211073466. Epub 2022 Feb 2.

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.抑制德尔塔浪潮：巴姆洛单抗-埃特司韦单抗、卡司瑞韦单抗-伊德韦单抗或索特罗韦单抗治疗轻度至中度 2019 冠状病毒病的临床结局。

Mayo Clin Proc. 2022 Sep;97(9):1641-1648. doi: 10.1016/j.mayocp.2022.06.015. Epub 2022 Jun 23.

The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2.针对 SARS-CoV 和 SARS-CoV-2 之间多种保守表位的中和抗体的广度。

Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2204256119. doi: 10.1073/pnas.2204256119. Epub 2022 Aug 16.

Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019.患者对轻度至中度2019冠状病毒病抗刺突单克隆抗体疗法的看法。

J Patient Exp. 2022 Jun 23;9:23743735221105673. doi: 10.1177/23743735221105673. eCollection 2022.

Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis.托珠单抗治疗 COVID-19 患者的疗效和危害：系统评价和荟萃分析。

PLoS One. 2022 Jun 3;17(6):e0269368. doi: 10.1371/journal.pone.0269368. eCollection 2022.

Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review.用于治疗和预防新冠肺炎的药物及疫苗的不良听觉前庭效应：综述

Audiol Res. 2022 Apr 29;12(3):224-248. doi: 10.3390/audiolres12030025.

Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.巴姆洛单抗-埃特司韦单抗和卡司瑞韦单抗-伊德维单抗治疗轻至中度 2019 冠状病毒病高危患者的严重结局发生率。

Mayo Clin Proc. 2022 May;97(5):943-950. doi: 10.1016/j.mayocp.2022.02.009. Epub 2022 Feb 23.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验